In the case of non-small cell lung cancers (NSCLC),2 mutational heterogeneity in epidermal growth factor (EGF) receptor (EGFR) provides one possible escape mechanism for patients exhibiting resistance to tyrosine kinase inhibitors (14, 15, 17, 18). Here, EGFR is linked to non-small cell lung carcinoma.